Dose and switching data as signatures for postmarketing ‘learning’
- At: 2004 FIP Congress in New Orleans (USA)
- Type: Presentation
- By: LEUFKENS, Hubert (Utrecht Institute Pharm Sci (UIPS), Pharmacoepidemiology and Pharmacotherapy, Utrecht, Netherlands)
Once a drug has been approved for marketing the ‘experiment’ of prescribing and actual usage of the medicine under normal clinical conditions starts. Drug development is a continuum ranging from fundamental, preclinical, clinical and postmarketing ‘learning’. The choice of the drug, the dose regimen and the duration of use are determined by a.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.